Open Access Open Access  Restricted Access Subscription or Fee Access

A Study and Report on Due (Drug Utilization Evaluation) of Cardiovascular and Endocrine Disorders/Diseases in Inpatient Units of Hospitals

Mekkanti Manasa Rekha, Umme Kulsum, Rinku Mathappan


In recent years drug utilization studies have become a potential tool to be used in the evaluation of health systems. On the process of drug utilization studies focus on factors related to prescribing, dispensing, administering, and taking of medication, and its associated events. Drug utilization data are available from databases- computerized or otherwise. From these databases different types of information, qualitative or quantitative or referring to a particular population are available. for collecting information on drug utilization Patient files and computer registries are widely used as instruments. depending upon the timing of data collection Prospective, Concurrent or Retrospective Drug Utilization studies may be used. Importance of drug utilization studies in pharmacoepidemiology has been increasing due to their close association to other areas like- public health, pharmacovigilance, Pharmacoeconomics and pharmacogenetics. This research article highlights various aspects, cycle, steps, need, scope, types, future perspectives. The Objective of the study is to evaluate the drug utilization pattern of drugs among the in-patient unit of cardiac and endocrine department of tertiary care hospital. By using a method of a prospective, interventional study was carried out in inpatient unit of cardiac and endocrine department of government ESI hospital Indiranagar, for a period of 6 months. Patient’s demographics, indications for admission, duration of hospital stay, and various drugs prescribed were observed and analyzed statistically. Resulted that a sample size of 180 patients with endocrine/cardiologic diseases were randomly opted for this study. The details of patient’s medication therapy were collected from patients through personal interview, case sheets, treatment charts and data collection forms. Determination and categorization required counselling by pharmacist in verbal about 88.8% were accepted. Out of 42 cases required communication between of DRPs were done using The PCNE classification scheme for Drug-Related Problems V5.01 by the pharmacist. The DRPs identified by pharmacist were reported and interventions made were documented. About 196 drug related problems were found in the study with the major problems being drug-drug interactions (13.7%) followed by generic substitution (10.2%). The mean drug related problem per patient was found to be 1.06. A total of 204 interventions were made by clinical pharmacist among which 114(55.8%) interventions were at prescriber level, 58(28.4%) interventions were at drug level, 17(8.3%) at the patient level and 15(7.3%) were other interventions or activities. Distribution based upon the degree of acceptance of interventions showed that among 59 drug regimen change interventions proposed by pharmacist, only 54.2% were accepted. Out of 70 monitoring required interventions made by pharmacist, about 78.5% were accepted. Among 18 cases pharmacist and other healthcare professionals a percentage of 88.8% was accepted and among 15 adverse drug reporting cases made in formal note form, 100% were accepted. The present study concludes that DUE (Drug Utilization Evaluation) as part of clinical practice plays a crucial role in identification of drug related problems which frequently happens in all investigated clinical department i.e., in endocrine or cardiology departments. Mean number of drugs per prescription were high. The prescribing pattern could be improved by reducing the number of drugs per prescription and by prescribing generic drugs to reduce the economic burden of the patients as these drugs are used for long time. Prescription Indicators recommended by the WHO can help the Health Care Centers to obtain better organization and improve healthcare attention to the public. An alarmingly low number of the drugs were mentioned by their generic names. Prescription of generic names can be recommended by the WHO can help the Health Care Centers to obtain better organization and improve healthcare attention to the public. The study recommends that there is a need for the regulatory agencies to develop a standard prescription format and implement it throughout the country. Also, it was observed during the study that irrational practices of prescribing the drugs are quite common. There is poor compliance of the physicians with WHO core prescribing indicators. Irrational prescribing is quite common, that is usually associated with various undesired drug effects, toxicities, tolerances, and resistance. Polypharmacy is quite common and the concept of generic prescribing in strict conditions must be implemented about the prescription and the administration of injectable drugs, and their use should be minimized to the extent possible.


Drug utilization, population, hospital , Drug-Related Problems , pharmacist

Full Text:



Sjoqvist F, Birkett D. Drug Utilization. In: Bramley DW editor. Introduction to Drug Utilization Research. (WHO booklet) New York: WHO office of publications; 2003. P.76-84.

WHO Expert Committee. The Selection of Essential Drugs, Technical Report Series no. 615. Geneva: World Health Organization, 1977.

Einarson T. Pharmcoepidemiology. In: Parthasarathi G, Hansen KN, Nahata MC, editors. A Text book of Clinical Pharmacy Practice- essential concepts and skills. 1st ed., Hyderabad: Universities Press (India) Limited; 2008. p.405-23.

Laporte JR, Porta M, Capella D. Drug utilization studies: A tool for determining the effectiveness of drug use. Br J ClinPharmac 1983; 16(3):301-04.

Andersen M. Is it possible to measure prescribing quality using only prescription data? Basic ClinPharmacolToxicol 2006; 98(3):314-19.

Wettermark B, Hammar N, Michael FC, Leimanis A, Otterblad OP, Bergman U, et al. The new Swedish Prescribed Drug Registeropportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16(7):72635.

Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998- 2005. Arch Intern Med 2007; 167(16):1752-59.

Baum C, Kennedy DL, Forbes MB, Jones JK. Drug use and expenditures in 1982. JAMA 1985; 253(3):382-86.

Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357(9271):1851-53.

Rosholm JU, Gram LF, Isacsson G, Hallas J, Bergman U. Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J ClinPharmacol 1997; 52(3):205-09.

Strom BL. Pharmacoepidemiology. 4th ed. Chichester, England:John Wiley & Sons, Ltd 2005.

Scheckler WE, Bennett JV. Antibiotic usage in seven community hospitals. JAMA 1970; 213(2):264-67.

Bergman U, Elmes P, Halse M, Halvorsen T, Hood H, Lunde PK, et al. The measurement of drug consumption- Drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J ClinPharmacol 1975; 8(2):83-89.

Boethius G, Wiman F. Recording of drug prescriptions in the country of Sweden. Methodological aspects. Eur J ClinPharmacol 1977; 12(1):31-35.

Bergman U, Andersen M, Vaccheri A, Bjerrum L, Wettermark B, Montanaro N. Deviations from evidence-based prescribing of nonsteroidal anti-inflammatory drugs in three European regions. Eur J ClinPharmacol 2000; 56(3):269-72.

Lunde PK, Baksaas I. Epidemiology of drug utilization- basic concepts and methodology. Acta Med ScandSuppl 1988; 721:7-11.

Costa J, Rosa MM, Ferreira JJ, Sampaio C, VazCarneiro A. Cardiac effects of acute poisoning with tricyclic antidepressants: systematic review of the literature. Part I. Rev Port Cardiol 2001; 20(10):671-78.

Naqvi SH, Dunkle LM, Timmerman KJ, Reichley RM, Stanley DL, O’Connor D. Antibiotic usage in a pediatric medical center. JAMA 1979; 242(18):1981-84.

Shapiro M, Townsend TR, Rosner B, Kass EH. Use of antimicrobial drugs in general hospitals. II. Analysis of patterns of use. J Infect Dis 1979; 139(6):698-706.

Castle M, Wilfert CM, Cate TR, Osterhout S. Antibiotic use at Duke University Medical Center. JAMA 1977; 237(26):2819-22.

Townsend TR, Shapiro M, Rosner B, Kass EH. Use of antimicrobial drugs in general hospitals: IV. Infants and children. Pediatrics 1979; 64(5):573-78.

Hartz I, Sakshaug S, Furu K, Engeland A, Eggen A, Njolstad I, et al. Aspects of statin prescribing in Norwegian countries with high, average and low statin consumption – an individual-level prescription database study. BMC ClinPharmacol 2007; 7:14.

Duarte RF, Cabrita J. Using a pharmaco-epidemiological approach to estimate diabetes type 2 prevalence in Portugal. Pharmacoepidemiol Drug Saf 2006; 15(4):269-74.

Neutel CI, Walop W. Comparing two different approaches to measuring drug use within the same survey. Chronic Dis Can 2000; 21(4):15056.

Cabrita J, Ferreira H, Iglesias P, Baptista T, Rocha E, Lopes da Silva A, et al. Patterns and determinants of psychoactive drug use in Lisbon University students-a population-based study. Pharm World Sci 2004; 26(2):79-82.

Rocha O, Lunet N, Costa L, Barros H. Osteoporosis treatment in Portugal: trends and geographical variation. Acta Med Port 2006; 19(5):37380.

de Oliveira MS, Soares MA, Foppe van Mil JW, Cabrita J. Inappropriate drug use by Portuguese elderly outpatients--effect of the Beers criteria update. Pharm World Sci 2006; 28(5):296-301.

Marques VP, Dias CM. Hypnotic consumption in the Portuguese population: data from the National Health Survey 1998-1999. Pharmacoepidemiol Drug Saf 2006; 15(1):63-69.

Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J ClinEpidemiol 1992; 45(6):683-92.

Johnson RE, Vollmer WM. Comparing sources of drug data about the elderly. J Am GeriatrSoc 1991; 39(11):1079-84.

Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J ClinEpidemiol 1997; 50(5):61925.

Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A. Influence of question structure on the recall of self-reported drug use. J ClinEpidemiol 2000; 53(3):273-77.

Van den Brandt PA, Petri H, Dorant E, Goldbohm RA, Van de Crommert S. Comparison of questionnaire information and pharmacy data on drug use. Pharm WeekblSci 1991; 13(2):91-96.

West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142(10):1103-12.

Goodman MT, Nomura AM, Wilkens LR, Kolonel LN. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 1990; 131(5):815-25.

USAID. Rational Pharmaceutical Management Plus (RPM Plus). (last modified Jan 10, 2013 08:45 AM). Available at:n .

G Parthasarathi, karin Nyfort-Hansen, Milap C Nahata. A text book of clinical pharmacist practice essential concepts and skills. 3-6-747/1/A and 3-6-754/1,himayatnagar, hyderabad 500029, Telangana,india: Universal press (india) private limited; 2004.

Oren J. Mechanic, et al. Acute Myocardial Infarction. (Last Update: August 11, 2021.) Available online at:

Medical News Today. Newman T. What to know about arrhythmia.Available online at:

Higuera V. Coronary artery disease: Causes, symptoms, and treatments. Available online at:

Holland K. High blood pressure (hypertension): Causes, symptoms, and more. Available online at:

Osborn CO. Hyperlipidemia: Symptoms, Causes, Treatment, and More. Available online at:

Holland K. Stroke: Symptoms, causes, treatment, types & more. Available online at:

Seladi-Schulman J. The endocrine system: Function, organs, hormones, and conditions. Available online at:

Watson S. Diabetes: Symptoms, causes, treatment, prevention, and more. Available online at:

Holland K. Hypothyroidism: Symptoms, causes, medication, diet & more. Available online at:

Wallace R 2015. Common thyroid gland diseases and problems to watch for Available online at:

Stang D. Everything you need to know about osteoporosis [Internet]. 2017.

Martel J. Low testosterone: Symptoms, diagnosis, and treatment [Internet]. 2017.

Watson S. Polycystic ovary syndrome (PCOS): Symptoms, causes, and treatment [Internet]. 2012.

Pittrow D, Kirch W, Bramlage P, Lehnert H, Höfler M, Unger T, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol. 2004;60(2):135–42.

Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care. 2017;40(4):468–75.

S. Lavanya*, G. Oliver Joel, S. Aswathy, A. Anju, M. M. Jintu, M. S. Sandra, D. Krishna kumar,A prospective study of drug utilization pattern of cardiac inotropes in cardiac intensive care unit at a tertiary care hospital Drug Invent Today 10 (2), 244-7, 2018.

Anuradha C R JR. Drug utilisation study in intensive cardiac care unit of a tertiary care hospital. University Journal of Medicine and Medical Specialities [Internet]. 2018.

Prasun Banerjee, Ananya Mandal, Dipankar Mukhopadhyay, Tanmoy Gangopadhyay, Sonai Mandal, Abhijit Das, Assessment of drug utilization pattern and rationality of drug use in treatment of dilated cardiomyopathy in a tertiary care teaching hospital of rural Bengal, International Journal of Basic & Clinical Pharmacology 6 (1), 123, 2017.

Bakos Z, Reitan C, Werther-Evaldsson A, Roijer A, Platonov P, Borgquist R. Cardiovascular drug utilization post-implant is related to clinical outcome in heart failure patients receiving cardiac resynchronization therapy. Cardiol J. 2017;24(4):374–84.

Montilla S, Marchesini G, Sammarco A, Trotta MP, Siviero PD, Tomino C, et al. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis. 2014;24(12):1346–53.

Alzubaidi N, Sharma M, Abdulmalik W, Habib A, Alhalmi A. Drug utilization study and adverse drug reaction reporting among patients using anticoagulants in a tertiary care teaching hospital. J Drug Deliv Ther. 2019;9(3-s):181–5.

Tasneem Sandozi, Fouzia Nausheen Drug utilization study in ischemic heart diseases associated with diabetes and hypertension Int J Pharma Bio Sci 1 (3), 1-4, 2010.

Praveen Choudhary, Jitendra M Agrawal, Supriya D Malhotra, Varsha J Patel Drug utilization pattern in acute coronary syndrome at tertiary care hospital: a prospective cross-sectional observational study International Journal of Basic & Clinical Pharmacology 5 (2), 513, 2016.

K Jyothi, TS Mohamed Saleem, L Vineela, C Gopinath, KB Yadavender Reddy, A retrospective drug utilization study of antiplatelet drugs in patients with ischemic heart diseasease. 2015:9(7):605-608.

Ankit Gaur, Kanad Deepak, Mahendra Singh Rathore, Amit Sharma, Irfanul Haque, Drug Utilization Evaluation of Coronary Artery Disease in a Tertiary Care Hospital in Punjab Research Journal of Pharmacy and Technology 12(1):149-155 January 2019.

Slathi I, Jadhav PR, Deb P, Verma S. Drug utilization study in Cardiology outpatient department at a tertiary care hospital. Int J Basic Clin Pharmacol. 2017;6(9):2276.

Kaur S, Rajagopalan S, Kaur N, Shafiq N, Bhalla A, Pandhi P, et al. Drug utilization study in medical emergency unit of a tertiary care hospital in north India. Emerg Med Int. 2014;2014:973578.

Kumar M, Dahiya V, Mishra S, Sharma D, Mishra N, Lahkar M. Cardiovascular disease prevalence and drug utilization patterns at a tertiary care hospital in northeastern India. Int J Pharm Pharm Sci. 20168(6);116–9.

Abhishek Ghosh, Asoke Kumar Das, Sushobhan Pramanik, Uttam Kumar Saha. Drug utilization study in patients of acute coronary syndrome on follow-up visits at a tertiary care centre in Kolkata. Asian Journal of Pharmacy and Life Science ISSN 2231, 4423, 2012.

Avula Naveen, MR Sravani, J Naresh Venkat, Drug utilization patterns in acute coronary syndrome at a tertiary care teaching hospital: A retrospective, non interventional and observational study, The Pharma Innovation 6 (9, Part H), 538, 2017.

Khalili H, Dashti-Khavidaki S, Talasaz AH-H, Najmedin F, Hosseinpoor R. Anticoagulant utilization evaluation in a teaching hospital: a prospective study: A prospective study. J Pharm Pract. 2010;23(6):579–84.

Yang YH, Kao SM, Chan KW. A retrospective drug utilization evaluation of antihyperlipidaemic agents in a medical centre in Taiwan. J Clin Pharm Ther. 1997;22(4):291–9.

Bachhav SS, Kshirsagar NA. Systematic review of drug utilization studies & the use of the drug classification system in the WHO-SEARO Region. Indian J Med Res. 2015;142(2):120–9.

Vinodkumar M, Ravishankar k, Aswinichand p, Satyanarayana v, Drug utilization evaluation bof cardiovascular drugs in outpatient department in a tertiary care hospital,International Journal of Current Research. 2015:7(09), pp.20693-20697, September, 2015.

Khalam A, Dilip C, Shinu C. Drug use evaluation of diabetes mellitus in hospitalized patients of a tertiary care referral hospital. J Basic Clin Physiol Pharmacol. 2012;23(4):173–7.

Ramachandran S, Swethanjali D, Hima BM, Devaki K, Sripada R, Deepak SE. Drug utilization evaluation on antidiabetic, thyroid and antithyroid drugs. Biomedical and Pharmacology Journal. 2020;13(4):1839–44.

M1* M, HadiHosnaei M, Adeli S, Moktan J, Sridhara Murthy NB, Jadidi J. A study on drug utilization of insulin and oral hypoglycemics in tertiary care hospital. J Nat Remedies. 2020;21(7(S3)):133–42.

Conwell LJ, Esposito D, Garavaglia S, Meadows ES, Colby M, Herrera V, et al. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis. Am J Geriatr Pharmacother. 2011;9(4):241–9.

Anne Klibanski, Lucile Adams-Campbell, Tamsen Bassford, Steven N. Blair, Scott D. Boden, Kay Dickersin, David R. Gifford, Lou Glasse, Steven R. Goldring, Keith Hruska, Susan R. Johnson, Laurie K. McCauley, William E. Russel, Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–95.

Rashid R, Geer MI, Verma SK, Rashid F, Ganaie A. Evaluation of prescription pattern and compliance in kashmiri women with polycystic ovarian syndrome. J Drug Deliv Ther. 2019;9(3):379–83.

Bird ST, Hartzema AG, Etminan M, Brophy JM, Delaney JAC. Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. Gynecol Endocrinol. 2013;29(4):365–9.

Altinok ML, Glintborg D, Depont Christensen R, Hallas J, Andersen M. Prescription of antidepressants is increased in Danish patients with polycystic ovary syndrome and is associated with hyperandrogenism. A population-based cohort study. Clin Endocrinol (Oxf). 2014;80(6):884–9.

Jia H, Sullivan CT, McCoy SC, Yarrow JF, Morrow M, Borst SE. Review of health risks of low testosterone and testosterone administration. World J Clin Cases. 2015;3(4):338–44.

H.Nagabushan, H.S.Roopadevi, Prakash, Pankaja, A prospective study of drug utilization pattern in cardiac intense care unit in a tertiary care teaching hospital. Karnataka. 2015:4(3):579-583.

Otoom S, Batieha A, Hadidi H, Hasan M, Al-Saudi K. Evaluation of drug use in Jordan using WHO patient care and health facility indicators. East Mediterr Heal J. 2002;8(4–5):544–9.

Pudasaini N, Singh C, Sagar GC, Sapkota S. Drug prescribing pattern and prescription error in elderly: A retrospective study of inpatient record. Asian J Pharm Clin Res. 2011;4(SUPPL. 1):83–6. 44. Kumari.

Kumari R, Idris M, Bhushan V, Khanna A, Agrawal M, Singh S. Assessment of prescription pattern at the public health facilities of Lucknow district. Indian J Pharmacol. 2008;40(6):243.

Isah A, Ross-Degnan D, Quick J, Laing R, Mabadeje A. The development of standard values for the WHO drug use prescribing indicators. In: International Conferences on Improving Use of Medicines (ICIUM). 2004:18(1):p. 1–6.

Hooper, R., Adam, A., Kheir, N. Pharmacist-documented interventions during the dispensing process in a primary health care facility in Qatar. Drug, healthcare and patient safety. 2009; 1: 73–80.


  • There are currently no refbacks.

Copyright (c) 2022 Trends in Drug Delivery